← Back to Investors

Adjuvant Capital

Global health impact investment fund focused on vaccines, infectious diseases, and global health challenges. Founded in partnership with CEPI, the Wellcome Trust, and other global health organizations.

Location
Washington, DC, USA
Founded
2017
AUM
$300M
Investment Range
$5M - $30M
Portfolio Companies
16
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth

Portfolio Companies

NameLocationFoundedCategories
PulmocideLondon, United Kingdom2013
biotechrespiratory+2
Excision BioTherapeuticsSan Francisco, California, USA2015
gene-editingcrispr+4
VitriVaxKansas City, Missouri, USA2013
vaccinesdrug-delivery+2
MinervaXCopenhagen, Denmark2010
vaccinesinfectious-disease+3
UnivercellsGosselies, Belgium2013
biotechbiomanufacturing+2
LakeShore BiopharmaShanghai, China & Bridgewater, New Jersey, USA2021
vaccinesbiologics+3
ChromaCodeCarlsbad, California, USA2015
molecular-diagnosticspcr+3
54geneLagos, Nigeria2019
genomicsafrican-genomics+3
CodagenixFarmingdale, New York, USA2012
vaccinessynthetic-biology+3
AN2 TherapeuticsMenlo Park, California, USA2018
biotechinfectious-disease+2
Themis BioscienceVienna, Austria2009
vaccinesinfectious-disease+3
InDevRBoulder, Colorado, USA2003
diagnosticsvaccines+2
X-Vax TechnologyNew York, New York, USA2015
vaccinesinfectious-disease+2
LimmaTech BiologicsBasel, Switzerland2010
biotechvaccines+3
Memo TherapeuticsBasel, Switzerland2018
biotechantibody-therapeutics+3
Antiva BiosciencesSan Francisco Bay Area, California, USA2014
biotechoncology+3